BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing ...
Ensoma’s lead program, EN-374, represents the first in vivo HSC-directed therapy for X-CGD, building on a mechanism that has been validated ex vivo. About Ensoma Ensoma is developing potentially ...
Learn how Elesa’s HSC and HSO sensors improve precision and durability in industrial applications. Read more now.
Company’s Phase 1/2 Clinical Trial of EN-374 in X-linked Chronic Granulomatous Disease is Now Open for Patient Enrollment BOSTON, September 22, 2025--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback